key: cord-0282608-16g8d3zg
authors: dos Santos, F.; Li, J. B.; Juocys, N.; Mazor, R.; Beretta, L.; Coufal, N. G.; Lam, M. T.; Odish, M. F.; Irigoyen, M. C.; O Donoghue, A. J.; Aletti, F.; Kistler, E. B.
title: Dysregulation of circulating protease activity in Covid-19-associated superinfection
date: 2021-10-22
journal: nan
DOI: 10.1101/2021.10.20.21265115
sha: d08d6cc54c3320717868a89877fdb16eb79b142b
doc_id: 282608
cord_uid: 16g8d3zg

Infection by SARS-CoV-2 and subsequent COVID-19 can cause viral sepsis and septic shock. Several complications have been observed in patients admitted to the intensive care unit (ICU) with COVID-19, one of those being bacterial superinfection. Based on prior evidence that dysregulated systemwide proteolysis is associated with death in bacterial septic shock, we investigated whether protease activity and proteolysis could be elevated in COVID-19-induced sepsis with bacterial superinfection. In particular, we sought to assess the possible implications on the regulation of protein systems, such as for instance the proteins and enzymes involved in the clotting cascade. Blood samples collected at multiple time points during the ICU stay of four COVID-19 patients were analyzed to quantify: a) the circulating proteome and peptidome by mass spectrometry; b) plasma enzymatic activity of trypsin-like substrates and five clotting factors (plasmin, thrombin, factor VII, factor IX, factor X) by a fluorogenic assay. Of the four patients, one was diagnosed with bacterial superinfection on day 7 after beginning of the study and later died. The other three patients all survived (ICU length-of-stay 11.25+-6.55 days, hospital stay of 15.25+-7.18 days). Spikes in protease activity (factor VII, trypsin-like activity) were detected on day 7 for the patient who died. Corresponding increases in the total intensity of peptides derived by hydrolysis of plasma proteins, especially of fibrinogen degradation products, and a general reduction of coagulation proteins, were measured as well. A downregulation of endogenous enzymatic inhibitors, in particular trypsin inhibitors, characterized the non-surviving patient throughout her ICU stay. Enzymatic activity was stable in the patients who survived. Our study highlights the potential of multiomics approaches, combined with quantitative analysis of enzymatic activity, to i) shed light on proteolysis as a possible pathological mechanism in sepsis and septic shock, including COVID-19-induced sepsis; ii) provide additional insight into malfunctioning protease-mediated systems, such as the coagulation cascade; and iii) describe the progression of COVID-19 with bacterial superinfection.

Infection by SARS-CoV-2 and subsequent COVID-19 can cause viral sepsis and septic 23

shock. Several complications have been observed in patients admitted to the intensive care 24 unit (ICU) with COVID-19, one of those being bacterial superinfection. Based on prior 25 evidence that dysregulated systemwide proteolysis is associated with death in bacterial septic 26 shock, we investigated whether protease activity and proteolysis could be elevated in COVID-27

19-induced sepsis with bacterial superinfection. In particular, we sought to assess the 28 possible implications on the regulation of protein systems, such as for instance the proteins 29 and enzymes involved in the clotting cascade. 30

Blood samples collected at multiple time points during the ICU stay of four COVID-19 patients 31 were analyzed to quantify: a) the circulating proteome and peptidome by mass spectrometry; 32 b) plasma enzymatic activity of trypsin-like substrates and five clotting factors (plasmin, 33 thrombin, factor VII, factor IX, factor X) by a fluorogenic assay. 34

Of the four patients, one was diagnosed with bacterial superinfection on day 7 after beginning 35 of the study and later died. The other three patients all survived (ICU length-of-stay 36 11.25±6.55 days, hospital stay of 15.25±7.18 days). Spikes in protease activity (factor VII, 37 trypsin-like activity) were detected on day 7 for the patient who died. Corresponding increases 38 in the total intensity of peptides derived by hydrolysis of plasma proteins, especially of 39 fibrinogen degradation products, and a general reduction of coagulation proteins, were 40 measured as well. A downregulation of endogenous enzymatic inhibitors, in particular trypsin 41 inhibitors, characterized the non-surviving patient throughout her ICU stay. Enzymatic activity 42 was stable in the patients who survived. 43

Our study highlights the potential of multiomics approaches, combined with quantitative 44 analysis of enzymatic activity, to i) shed light on proteolysis as a possible pathological 45 mechanism in sepsis and septic shock, including COVID-19-induced sepsis; ii) provide 46

The Coronavirus disease (COVID-19) pandemic is caused by viral infection with the 51 coronavirus SARS-CoV-2. Affecting every organ of the body following initial infection of the 52 respiratory system, this highly contagious virus has contributed to the deaths of almost 5 53 million people to date. Despite the emphasis on COVID-19 research, our understanding of 54 the disease remains incomplete and therapeutic options are limited (1-7). Frequent and fatal 55 complications arising from SARS-CoV-2-induced sepsis include cytokine storm and 56 coagulopathies (8,9). Less frequent (10), but not less dangerous, bacterial superinfections 57 make the clinical treatment of COVID-19 patients in the intensive care unit (ICU) even more 58 challenging, especially because of the lack of sound hypotheses as to the underlying 59 pathology and interplay between viral and bacterial infection and their clinical implications 60 (11). 61

We have previously shown, in both animal and human studies, that a possible pathological 62 mechanism triggered by acute illness, including bacterial sepsis and septic shock, is 63 dysregulated proteolysis (12) (13) (14) (15) . Major protease-mediated systems are known to be affected 64 in critical illness, including activation of the coagulation and complement cascades. To better 65 understand the possible relationship between systemic proteolysis occurring in shock, 66

including COVID-19-induced septic shock and the malfunction of these protease-mediated 67 systems, we have developed a complex, multimodal approach to assess protease activity 68 and proteolysis in plasma, consisting of quantitative enzymatic activity assays and mass 69 spectrometry-based multi-omics analyses of the circulating proteome and peptidome. The 70 utilization of these techniques has shown promising results in the ability to i) estimate in vivo 71 proteolysis in plasma as a marker of ongoing systemic proteolysis during shock (13,14) and 72

ii) detect circulating peptidase activity (16). 73

The hypothesis of this study was that a complex, dynamic description of plasma proteins and 74 the activity of some of their most important circulating enzymatic substrates can be leveraged 75 as a tool to shed light on the progression of COVID-19 and the risk for fatal complications, 76 especially in the presence of bacterial superinfection and diagnosis of sepsis and septic 77

shock. The specific goals that we aimed to investigate were to assess: 1) the patterns of 78 protease activity in the plasma of COVID-19 patients following admission to the ICU by means 79 of quantitative analysis of enzymatic activity; 2) the relationship between alterations in 80 protease activity over time during ICU stay and the development of bacterial superinfection; 81

3) the possible implications of dysregulated proteolysis on major protein systems (e.g., 82

clotting proteins and enzymes) by analysis of plasma proteomics and peptidomics. 

This was a prospective observational study. The University of California, San Diego 88

Institutional Review Board (IRB) provided approval of the study conduct (IRB# 190699, 89 Protocol #20-0006); informed consent was obtained for the collection of blood samples and San Diego Medical Center between April 01, 2020, and May 30, 2020, was enrolled in the 94 study. De-identified demographic and prior health history data were obtained. Three healthy 95 subjects were enrolled as a control group for enzymatic activity assays. 96 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Standard laboratory measurements were obtained as necessary for optimal patient care by 97 the UC San Diego Medical Center for Advanced Laboratory Medicine (CALM) laboratories as 98 part of regular and usual care. No additional laboratory data were collected. 99

All non-standard laboratory assays, including protease activity assays and mass The clinical data acquisition and blood sample collection started on the day following protocol 111 study consent (usually day of ICU admission) and was repeated on the following day and 112 every other day thereafter until patient discharge or death. 113 114

To test the enzymatic activity in COVID-19 plasma samples, we selected a variety of 116 fluorogenic substrates, with a specific focus on enzymes with trypsin-like activity and clotting 117 factors. All plasma samples were processed and analyzed simultaneously for each substrate, 118

including healthy control plasma. The peptide sequences used in this assay were chosen as 119 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 22, 2021. ; https://doi.org/10.1101/2021.10.20.21265115 doi: medRxiv preprint substrates for coagulation factor enzymes, tryptic enzymes in general, as well as 120 endopeptidase activity (Supplementary File 1) . Briefly, a 384-well plate was used to combine 121 15μL of plasma (1/50 final dilution in PBS, pH=7.4) with 15μL of each substrate (5μM in PBS) 122 in triplicate wells and immediately measured for activity with a spectrophotometer (FilterMax 123 

All plasma samples from the COVID-19 patients were subjected to a series of protein 134 extraction and pretreatment steps prior to mass spectrometry. The complete protocols for 135 plasma sample preparation, processing and data analysis steps can be found in 136

Supplementary File 1. Briefly, for proteomics measurements, proteins were precipitated 137 from the plasma samples, treated with denaturing, reducing, and alkylating reagents, and 138 enzymatically digested with trypsin. To quantify peptides in plasma, high molecular weight 139 proteins were first removed following addition of methanol and the remaining peptide 140 quantified by LC-MS/MS. PEAKS Studio 8.5 (Bioinformatics Solutions, Inc.) proteomics 141 software was used for protein identification and quantification. 142 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For the purposes of our study, the analysis of the circulating proteome and peptidome focused 143 on three main groups of proteins, according to their function: 1) coagulation; 2) complement 144 system, immune response and inflammation; and 3) endogenous protease inhibitors. Each 145 of these systems is known to be affected by acute illness, and their clinical management (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. analysis were comprised of three males and one female and ranged in age from 29-88 years. 169

Reflecting the overall demographics of the COVID-19 epidemic in San Diego, three of the 170 subjects were Hispanic. One patient, who will be referred to as "Patient 3" in the following, 171 was diagnosed with bacterial superinfection and subsequent sepsis on day 7 and died on day 172 16 of her ICU stay. The remainder (Patients 1, 2 and 4) were discharged from the ICU with a 173 mean ICU length-of-stay for all subjects of 11.25±6.55 days and mean hospital stay of 174 15.25±7.18 days. Body mass index (BMI) was 28.84±3.65 kg/m² (range: 29.4-32.14 kg/m²) 175 and self-described baseline health was either "fit" or "well". 176

All patients were initially treated with azithromycin. The three surviving subjects, who did not 177 present with a bacterial superinfection, were also treated with ceftriaxone. Patient 3 was 178 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Enzymatic activity data are reported in Figure 1 (coagulation enzymes) and in Figure 2  191 (trypsin-like enzymes and exopeptidases). Figure 1 shows that plasmin activity remained 192 stable over time and between patients, serving as internal control of enzymatic activity. 193

Thrombin and Factor IX activity showed an increasing trend over the first five days of ICU 194 admission followed by decrease. Factor X activity decreased over time in Patients 1 and 2 195 compared to day 2 and increased in Patients 3 and 4. The main finding was the marked 196 increase in Factor VII activity and tryptic-like activity, particularly at a terminal Val-Arg ( Figure  197 2) in Patient 3 on day 7, when bacterial superinfection was diagnosed. 198 The sum of the intensities of all the peptide fragments detected at each time point from a total 235 of 233 source proteins suggests marked proteolytic activity in Patient 3 on day 7 ( Figure 4A) . 236

This ongoing protein degradation was particularly evident in fibrinogen-α and fibrinogen-β 237 (Figure 4B and 4C) . Of note, peptides derived from α2-antiplasmin had a characteristic trend 238 in Patients 1, 3 and 4, with a progressive increase until day 5, followed by an abrupt reduction 239 and a progressive increase thereafter. Figure 4E shows the unique patterns of protein 240 cleavage for fibrinogen-α obtained by Peptigram analysis and the size and location of the 241 fragments that suggest that the enhanced proteolytic activity seen on day 7 in Patient 3 242 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Omics approaches (metabolomics, proteomics, peptidomics, transcriptomics, genomics) to 254 study disease, including acute illness, have become increasingly popular due to the unique 255 multiscale insights they provide that can result in better targeted treatments (12, 14, (18) (19) (20) (21) (22) (23) . 256

Several contributions have already been made to the field of COVID-19 by proteomics (24-257

We have previously leveraged -omics analyses to test the hypothesis that dysregulated 259 systemic proteolysis occurs in circulatory shock using a peptidomic-based assay, which 260 estimates proteolysis by assessing the abundance and count of circulating peptides (13,14) . 261

Analysis of the plasma peptidome by this method showed an association between enhanced 262 proteolysis and death (14) in septic shock caused by bacterial infection. Therefore, we 263 investigated whether a similar association may also be found in viral sepsis caused by 264

To better characterize and quantify the dynamic aspect of systemic intravascular proteolysis, 266 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 22, 2021. ; https://doi.org/10.1101/2021.10.20.21265115 doi: medRxiv preprint proteolytic activity generated by proteases that are known to be activated in acute illness, 267 such as clotting factors and other serine proteases were measured. 268

Protease activity patterns showed a marked increase of Factor VII and Factor IX activity on 269 day 7 in the patient who died of superinfection. In particular, the spike in Factor VII activity 270 was unique amongst our sample cohort and represents an 80-fold increase in activity relative 271 to that found in healthy control plasma. Further, the same trend in activity was also found in (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 22, 2021. ; https://doi.org/10.1101/2021.10.20.21265115 doi: medRxiv preprint progression of COVID-19 infection. This was apparent clinically in Patient 3 who had been on 291 either phenylephrine or norepinephrine (but not both) for hypotension from admission to the 292 ICU, and on day 7 necessitated the addition of two simultaneous pressor agents 293 (norepinephrine and vasopressin) to maintain adequate hemodynamics. This pressor 294 requirement subsequently increased the following day to three simultaneous pressor agents 295 (norepinephrine, phenylephrine, and vasopressin) before later subsiding. pathological mechanisms (i.e., proteolysis) that contribute to poor outcomes; ii) the 306 relationship between enzymatic activity patterns and bacterial superinfection that causes 307 further illness, in addition to that already seen with precedent viral infection. 308

The association between disease severity and -omics patterns is also supported by the 309 measurements of other proteins that play a role in immunity and inflammation. For instance, 310 the trends in expression of ficolin-1 and VEGFR2, and to some extent C-reactive protein 311

(which showed a decrease over time in all four patients, much milder in Patient 3 though) 312

correlate with the exacerbation of the inflammatory state of Patient 3 following diagnosis of 313 bacterial superinfection. Ficolin-1 is a known activator of the complement system and innate 314 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 22, 2021. ; https://doi.org/10.1101/2021.10.20.21265115 doi: medRxiv preprint immunity through recognition of pathogen-associated molecular patterns (PAMPs) (31,32), 315 while VEGFR2 has been related to COVID-19 progression (33) as also suggested by the 316 hypothesis that the VEGF receptor activator (PMC18457) may serve as a biomarker for 317 detecting the progression of COVID-19 (34). In fact, the patient with the least severe course 318 of disease (Patient 2) had the lowest VEGFR2 intensity and, importantly, was the only patient 319 who was not diagnosed with ARDS. Patient 4, on the other hand, had rheumatoid arthritis 320 and subsequently greater VEGFR2 intensity. These observations highlight that the complexity 321 of the interplay between baseline comorbidities, severity of the disease and variability of the 322 features of immune and inflammatory responses prevents from interpreting conclusively the 323 expression trends of complement factors and warrants further research in the future. 324

There are some limitations of this study that need to be acknowledged. First, regarding the 325 clinically (obtained from the patient record) derived data, the low sample size of the studied 326 patient population and non-uniformity in the timing of some laboratory results hinders the 327 ability to make stronger inferences than are made here; the robustness of the presented 328 results would doubtlessly have been strengthened with a larger sample size and fewer 329 missing data. However, even with this very limited sample size we were able to make some 330 cautious conclusions as to new hypotheses of molecular mechanisms that might otherwise 331 not be recognized with a larger patient population. Second, regarding data drop-out, this was 332 a real-world observational study, and the clinical laboratory measurements and values reflect 333 patient management of severely ill COVID+ patients in the ICU. Third, in our analytical 334 protocol, the mass spectrometry approach was necessarily untargeted; if specific protein 335 systems and products of their degradation were targeted, it is possible that the potential 336 dysfunction in these systems (e.g., coagulation, complement, etc.) could be highlighted in 337 greater detail. Finally, when comparing and integrating proteomics and peptidomics data, the 338 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 22, 2021. ; https://doi.org/10.1101/2021.10.20.21265115 doi: medRxiv preprint availability of transcriptomics data, which were not part of the experimental design of this 339

observational study, could add information on protein regulation, and help understand to a 340 greater depth the impact of abnormal proteolysis and protein synthesis, breakdown, and 341 turnover. 342

In conclusion, we demonstrate here that the analysis of the circulating proteome and 343 peptidome, coupled with quantitation of enzymatic activity in plasma of COVID-19 patients, 344

provides additional data about the progression of the disease. Our approach could prove 345 particularly useful for achieving a more comprehensive description of the impairment of the 346 activation and regulation of coagulation, a complex, protease-mediated system which plays 

The authors declare that the research was conducted in the absence of any commercial or 356 financial relationships that could be construed as a potential conflict of interest. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

ShockOmics: 415 multiscale approach to the identification of molecular biomarkers in acute heart failure 416 induced by shock

Peptidomic Analysis of Rat Plasma: Proteolysis in Hemorrhagic Shock

Proteolysis in septic shock patients: plasma peptidomic patterns are associated with 423 mortality

Continuous enteral protease inhibition as a novel treatment for experimental 426 trauma/hemorrhagic shock

High-Resolution Mass 429 Spectrometry-Based Approaches for the Detection and Quantification of Peptidase 430 Activity in Plasma

Ferrario 435 M. Characterization of a metabolomic profile associated with responsiveness to therapy 436 in the acute phase of septic shock

Proteomic study revealed cellular 439 assembly and lipid metabolism dysregulation in sepsis secondary to community-440 acquired pneumonia

An Innovative Approach 443 for The Integration of Proteomics and Metabolomics Data In Severe Septic Shock 444 Patients Stratified for Mortality

A longitudinal study highlights shared aspects of the transcriptomic 447 response to cardiogenic and septic shock

Sepsis: deriving biological meaning and clinical applications from high-dimensional data

Toward 452 rapid sepsis diagnosis and patient stratification: What's new from microbiology and omics 453 Science

Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of 455 COVID-19 Infection

A time-resolved proteomic and prognostic map of COVID-19

Proteomic Approaches 459 to Study SARS-CoV-2 Biology and COVID-19 Pathology

Discovery 463 Proteomics for COVID-19: Where We Are Now

Corsi Romanelli 466 M. Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and 467 Fibrinolysis Leading the Outcome

Coagulopathy in COVID-19

COVID-19-associated coagulopathy and disseminated 471 intravascular coagulation

Ficolins and the Recognition of Pathogenic 473 Microorganisms: An Overview of the Innate Immune Response and Contribution of 474 Single Nucleotide Polymorphisms

Rationale for targeting complement in COVID-19

Between inflammation and 480 thrombosis: endothelial cells in COVID-19

VEGF-D: a novel biomarker for detection 482 of COVID-19 progression

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity